NN 9161

Drug Profile

NN 9161

Alternative Names: '2-0453; NN9161; NNC0070-0002-0453

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Class Obesity therapies; Proteins
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 30 Nov 2011 Discontinued - Phase-I/II for Obesity in USA (SC)
  • 13 Jul 2010 Novo Nordisk completes enrolment in its phase I/II trial (NCT01044108) for Obesity in USA
  • 06 Jan 2010 Phase-I/II clinical trials in Obesity in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top